

# MEDICAL POLICY STATEMENT

## Ohio Medicaid

| Policy Name & Number                                            | Date Effective |
|-----------------------------------------------------------------|----------------|
| Non-Invasive Home Mechanical Ventilation (E0466)-OH MCD-MM-1588 | 10/01/2026     |
| Policy Type                                                     |                |
| MEDICAL                                                         |                |

Medical Policy Statements are developed from a review of the available evidence-based, clinical information based on and supported by clinical guidelines from medical specialties, peer-reviewed medical and scientific studies, nationally recognized utilization and technology assessment guidelines, and other medical management industry standards to aid in determining the medical necessity of a service. Medically necessary services are defined in the plan-specific Evidence of Coverage, Member Handbooks, Provider Manuals, Medical Policy Statements, and/or other plan policies and procedures.

Medical Policy Statements do not guarantee an authorization or payment of services. Please refer to the plan contract (e.g., Evidence of Coverage, Member Handbook) for the service(s) referenced in the Medical Policy Statement. Except as otherwise required by law, if there is a conflict between the Medical Policy Statement and the plan contract and/or provider agreement, then the plan contract and/or provider agreement will be the controlling document. Reasonable discretion may be used in interpreting and applying this Policy Statement to services provided in a particular case, and the policy may be modified at any time. Medical Policy Statements may be superseded by federal and state laws and regulations, as applicable. In the case of a discrepancy between the Policy Statement's effective date and any applicable legal or regulatory requirement, the law or regulation will govern.

Coverage for mental health and substance use disorder (MH/SUD) benefits are provided at the same level as coverage for medical and surgical (M/S) benefits, as required by the Mental Health Parity and Addiction Equity Act (MHPAEA). MH/SUD benefits are not subject to limits or requirements that are more restrictive than those that apply to M/S benefits.

### Table of Contents

|                                  |   |
|----------------------------------|---|
| A. Subject .....                 | 2 |
| B. Background .....              | 2 |
| C. Definitions.....              | 2 |
| D. Policy .....                  | 3 |
| E. Conditions of Coverage .....  | 8 |
| F. Related Policies/Rules .....  | 9 |
| G. Review/Revision History ..... | 9 |
| H. References .....              | 9 |

A. Subject

**Non-Invasive Home Mechanical Ventilation (E0466)**

B. Background

This document outlines the medical necessity criteria for a non-invasive home ventilator for a member with stable, chronic respiratory failure. This device does not treat the underlying cause of respiratory failure but functions as supportive therapy, which may include reducing symptoms, improving quality of life, or sustaining or extending life. It may be used intermittently during the day and/or during sleep.

A non-invasive home ventilator will not be reimbursed as such when its sole purpose is to function as a respiratory assistance device, including continuous positive airway pressure (CPAP), auto-titrating PAP, and bilevel airway pressure (BIPAP). Medical necessity for BIPAP and CPAP devices are determined based upon MCG criteria, A-0431 and A-0994.

C. Definitions

- **Apnea-Hypopnea Index (AHI)** – The combined average number of episodes of apnea or hypopneas recorded over a period of at least 2 hours without the use of a respiratory device, reported by polysomnogram. Extrapolation or projection of the AHI is not permitted.

| <b>Apnea-Hypopnea Index (AHI)</b> |                  |                      |
|-----------------------------------|------------------|----------------------|
|                                   | <b>Adult AHI</b> | <b>Pediatric AHI</b> |
| <b>Mild OSA</b>                   | 5 -14            | 1 - 4.9              |
| <b>Moderate OSA</b>               | 15 - 30          | 5 - 9.9              |
| <b>Severe OSA</b>                 | > 30             | > 10                 |

- **Home Mechanical Ventilation (HMV)** – An overarching term used in this policy to describe home-based ventilatory support devices used in the management of chronic respiratory failure, encompassing a continuum of non-invasive respiratory support modalities, including respiratory assist devices (eg, CPAP, Bilevel, and volume-targeted pressure support modes such as AVAPS) and, when medically necessary, non-invasive home ventilator devices (eg, E0466). For purposes of this policy, classification within the HMV continuum is determined by clinical dependence, functional capability of the device, and medical necessity, rather than by device naming conventions alone. This policy does not address invasive mechanical ventilation delivered via tracheostomy.
- **Non-Invasive Ventilation (NIV) / Non-Invasive Home Ventilator** – Refers to ventilatory support delivered through a non-invasive interface (eg, nasal or oronasal mask or mouthpiece) using positive airway pressure technology and includes both respiratory assist device (RADS) modes that augment spontaneous breathing and non-invasive mechanical ventilation that delivers mandatory, machine-generated breaths.
- **Respiratory Assist Devices (RADs)** – Non-invasive positive airway pressure devices, including standard BIPAP, and volume-targeted pressure support modes such as AVAPs or iVAPs, that augment spontaneous breathing but do not provide

- mandatory, machine-generated breaths as the primary source of ventilation and therefore do not constitute ventilator dependency as defined within this policy. RADs are billed under E0601, E0470, E0471, and E0472.
- **Bi-level Positive Airway Pressure (BIPAP) Device** – A device that uses mild bi-level or 2 levels of air pressure to keep breathing airways open.
  - **Continuous Positive Airway Pressure (CPAP) Device** – A device that uses mild continuous air pressure to keep breathing airways open.
  - **Auto EPAP (AE)** – An automated feature that adjusts expiratory positive airway pressure (EPAP) in response to airflow limitation/upper airway obstruction during non-invasive therapy.
  - **Average Volume Assured Pressure Supports (AVAPS), with or without Auto-EPAP (AE)** – A volume-targeted mode of non-invasive positive airway pressure ventilation that delivers variable pressure support within prescribed limits to achieve a target ventilation (typically via a target tidal volume) and functions as a respiratory assist device that augments spontaneous breathing, rather than as a life-sustaining ventilator.
  - **Intelligent Volume Assured Pressure Support (iVAPS)** – A mode of non-invasive ventilation that adjusts positive airway pressure support over time to achieve a target ventilation goal while relying on the patient's spontaneous breathing effort, similar in function to AVAPS.
  - **Ventilator-Dependent (Non-Invasive)** – Describes a member who requires a device to provide mandatory, mechanical ventilation that serves as the primary, life-sustaining source of ventilation for 6 or more hours within a 24-hour period, and who cannot safely maintain adequate ventilation without such mechanical assistance. Discontinuation of ventilatory support would place the member at risk of serious harm or death. Use of CPAP, standard bilevel positive airway pressure devices, or volume targeted pressure support modes (eg, AVAPS or iVAPS), when used to treat sleep apnea or mild to moderate respiratory insufficiency and to augment spontaneous breathing, does not constitute ventilator dependence and such devices are not considered non-invasive home ventilators under this policy.

#### D. Policy

The criteria below are intended to guide escalation from CPAP or BIPAP to a non-invasive home ventilator (E0466) only when the member's chronic respiratory failure and clinical dependence require ventilator-level support beyond the capabilities of RADs. CareSource utilizes Ohio Administrative Code and MCG Health criteria to determine medical necessity for non-invasive home ventilator devices (ie, HVD; E0466). Requests that do not meet the criteria for HVD will be reviewed against MCG Health criteria for BIPAP and CPAP devices (ie, A-0431 and A-0994).

- I. An initial approval for HVD is valid for a maximum of 3 months. A new medical necessity determination thereafter is required every 6 months with supporting documentation for continued rental use.

- II. Medical Necessity Criteria for Initial Rental of Home Ventilatory Device
- Medical necessity for the initial coverage of non-invasive HVD is based upon the following conditions in II - IV being met:
- A. Congenital central hypoventilation syndrome
  - B. Chronic lung disease of infancy (eg, bronchopulmonary dysplasia), and patient unable to maintain acceptable pH and PCO<sub>2</sub> without ventilator support
  - C. Chronic obstructive pulmonary disease (COPD) and **ONE OR MORE** of the following:
    1. Chronic hypercapnia (ie, PaCO<sub>2</sub> > 45 mm Hg (6.0 kPa)) in stable patient
    2. Non-invasive ventilation during hospitalization with persistent hypercapnia during spontaneous breathing (ie, PaCO<sub>2</sub> > 45 mm Hg (6.0 kPa))
    3. Palliative care for end-stage disease and advance directive states no desire for intubation
  - D. Neuromuscular disorder accompanied by respiratory failure, as indicated by **ALL** the following:
    1. Appropriate neuromuscular disorder, as indicated by **ONE OR MORE** of the following:
      - a. amyotrophic lateral sclerosis
      - b. congenital muscular dystrophy
      - c. Duchenne muscular dystrophy
      - d. mitochondrial myopathy
      - e. myotonic dystrophy
      - f. postpolio syndrome
      - g. spinal cord syndrome
      - h. spinal muscular atrophy
      - i. other neuromuscular disorder accompanied by chronic respiratory failure (eg, multiple sclerosis, myasthenia gravis, Pompe disease)
    2. Documentation of respiratory failure, as indicated by **ONE OR MORE**:
      - a. Daytime PCO<sub>2</sub> (arterial or capillary) greater than 45 mm Hg (6.0 kPa)
      - b. Forced vital capacity less than 50% predicted
      - c. Forced vital capacity less than 80% predicted and symptoms of respiratory failure
      - d. Maximum inspiratory pressure 60 cm H<sub>2</sub>O (5884 Pa) or lower
      - e. Maximum sniff nasal inspiratory pressure less than 40 cm H<sub>2</sub>O (3923 Pa)
      - f. Oxygen saturation less than 88% for 5 consecutive minutes during nocturnal oximetry
      - g. Polysomnography demonstrates sleep hypoventilation, as indicated by **ONE OR MORE** of the following:
        - i. Adult with sleep-related hypoventilation (ie, arterial, end-tidal, or transcutaneous PCO<sub>2</sub> greater than 55 mm Hg (7.3 kPa) for 10 minutes or longer, or increase in arterial, end-tidal, or transcutaneous PCO<sub>2</sub> of 10 mm Hg (1.3 kPa) or greater above awake supine value resulting in PCO<sub>2</sub> greater than 50 mm Hg (6.7 kPa) for 10 minutes or longer).
        - ii. Child with sleep-related hypoventilation (ie, sleeping arterial, end-tidal, or transcutaneous PCO<sub>2</sub> of greater than 50 mm Hg (6.7 kPa) for

greater than 25% of total sleep time, or peak sleep end-tidal PCO<sub>2</sub> of 55 mm Hg (7.3 kPa) or greater).

- E. Obesity hypoventilation syndrome, as indicated by **ALL** of the following:
  1. BMI > 30
  2. CPAP unsuccessful or not appropriate, as indicated by **ONE OR MORE** of the following:
    - a. Comorbid sleep-related hypoventilation (ie, arterial, end-tidal, or transcutaneous PCO<sub>2</sub> greater than 55mm Hg (7.3 kPa) for 10 minutes or longer, or increase in arterial, end-tidal, or transcutaneous PCO<sub>2</sub> of 10 mm Hg (1.3 kPa) or greater above awake supine value resulting in PCO<sub>2</sub> greater than 50 mm Hg (6.7 kPa) for 10 minutes or longer)
    - b. Intolerance of CPAP pressures necessary to correct obstructive sleep apnea (OSA) component (ie, difficulty exhaling against fixed airway pressure)
    - c. Lack of resolution of hypercarbia, nocturnal desaturation, and OSA despite 3 months of CPAP use
    - d. Titration study demonstrates OSA despite CPAP 15 cm H<sub>2</sub>O (1471 Pa) that is responsive to BIPAP
  3. Daytime hypercapnia with PaCO<sub>2</sub> greater than 45 mm Hg (6.0 kPa) without other etiology (eg, kyphoscoliosis, lung parenchymal disease, myopathy, severe hypothyroidism)
  4. Sleep-disordered breathing or hypoventilation on polysomnography, as indicated by **ONE OR MORE** of the following:
    - a. Apnea-hypopnea index of 5 or greater
    - b. Increase in PaCO<sub>2</sub> during sleep by more than 10 mm Hg (1.3 kPa) above value while awake
    - c. Significant oxygen desaturation (eg, less than 90%) not explained by obstructive apneas or hypopneas
  5. TSH level does not demonstrate hypothyroidism
- F. OSA in child or adolescent and **ONE OR MORE** of the following:
  1. Mild OSA (ie, apnea-hypopnea index from 1 to 5) and **ONE OR MORE** of the following:
    - a. achondroplasia
    - b. behavioral problems
    - c. cardiovascular disease (eg, elevated blood pressure, pulmonary hypertension)
    - d. Chiari malformation
    - e. craniofacial abnormalities
    - f. Down Syndrome
    - g. excessive daytime sleepiness
    - h. impaired cognition
    - i. inattention or hyperactivity
    - j. mucopolysaccharidoses
    - k. neuromuscular disorders
    - l. Prader-Willi syndrome
  2. Moderate or severe OSA (ie, apnea-hypopnea index greater than 5)

3. Residual apnea-hypopnea index greater than 5 in pediatric patient after adenotonsillectomy
- G. Restrictive disorder of chest wall, as indicated by **ALL** of the following:
  1. Appropriate chest wall disorder as indicated by **ONE OR MORE** of the following:
    - a. asphyxiating thoracic dystrophy
    - b. kyphoscoliosis
    - c. other chest wall disorder accompanied by chronic respiratory failure (eg, ankylosing spondylitis, fibrothorax, post-tuberculous chest wall deformity)
  2. Documentation of respiratory failure as indicated by **ONE OR MORE** of the following:
    - a. Arterial O<sub>2</sub> saturation less than 88% for 5 consecutive minutes during nocturnal oximetry
    - b. Daytime PCO<sub>2</sub> (arterial or capillary) greater than 45 mm Hg (6.0 kPa)
    - c. Forced vital capacity less than 50% predicted
    - d. Forced vital capacity less than 80% predicted and symptoms of respiratory failure
    - e. Maximum inspiratory pressure 60 cm H<sub>2</sub>O (5884 Pa) or lower
    - f. Polysomnography demonstrates sleep hypoventilation, as indicated by **ONE OR MORE** of the following:
      01. Adult with sleep-related hypoventilation (ie, arterial, end-tidal, or transcutaneous PCO<sub>2</sub> greater than 55 mm Hg (7.3 kPa) for 10 minutes or longer, or increase in arterial, end-tidal, or transcutaneous PCO<sub>2</sub> of 10 mm Hg (1.3 kPa) or greater above awake supine value resulting in PCO<sub>2</sub> greater than 50 mm Hg (6.7 kPa) for 10 minutes or longer).
      02. Child with sleep-related hypoventilation (ie, sleeping arterial, end-tidal, or transcutaneous PCO<sub>2</sub> of greater than 50 mm Hg (6.7 kPa) for greater than 25% of total sleep time, or peak sleep end-tidal PCO<sub>2</sub> of 55 mm Hg (7.3 kPa) or greater).
- III. Respiratory status is STABLE, as indicated by **ALL** of the following:
  - A. Airway interface is safe with a non-invasive interface with acceptable fit.
  - B. Airway pressure requirement appropriate, as indicated by **ONE OR MORE** of the following:
    1. BIPAP expiratory positive airway pressure requirement is ≤ 10 cm H<sub>2</sub>O (981 Pa).
    2. CPAP pressure requirement in child is ≤ 15 cm H<sub>2</sub>O (1471 Pa).
    3. Ventilator positive end-expiratory pressure requirement is ≤ 10 cm H<sub>2</sub>O (981 Pa).
  - C. Oxygen requirement does not exceed 40% FiO<sub>2</sub>.
  - D. Settings are stable on chosen device.
  - E. No continuous invasive monitoring is required.
- IV. The criteria below define when a member's clinical needs exceed the capabilities of CPAP or standard BIPAP, such that consideration of a non-invasive home ventilator

- (E0466) is appropriate. A BIPAP or CPAP device must not be clinically appropriate as indicated by **ONE OR MORE** of the following.
- A. Chronic respiratory insufficiency fails to improve with simple BIPAP device.
  - B. Infant or child does not meet the minimum body weight requirement for CPAP device.
  - C. Infant or child is not appropriate for simple BIPAP device due to setting or performance requirements, as indicated by **ONE OR MORE** of the following:
    - 1. Breath rates delivered by device not appropriate for patient.
    - 2. Compatible ventilator circuits not appropriate for patient (eg, circuit compliance, compressed volume, dead space).
    - 3. Inspiratory flows delivered by device not appropriate for patient.
    - 4. Patient does not meet ventilator minimum body weight requirements.
    - 5. Pressure range (eg, expiratory pressure, inspiratory pressure) not appropriate for patient.
    - 6. Tidal volume range delivered by device not appropriate for patient.
    - 7. Ventilator inspiratory trigger delay (ie, airway pressure rise time) not appropriate for patient.
    - 8. Ventilator inspiratory trigger sensitivity not appropriate for patient.
  - D. The following setting or functionality is required by the member and is not available with simple BIPAP device:
    - 1. Alarms required by member are not available on the device.
    - 2. Daytime ventilation using mouthpiece is required.
    - 3. Pressure range delivered by device is not appropriate for member.
    - 4. Member requires volume-assured pressure support or volume control mode (eg, obesity hypoventilation syndrome).
  - E. Portable ventilator is required for mobility.
  - F. Ventilated patient requires cough assistance via volume ventilator's breath stacking capability.
  - G. Ventilation is required 24 hours per day.
- V. Medical Necessity for Continued Device Use
- For HVD continued use beyond the initial 3-month determination, medical necessity must be reestablished every 6 months thereafter. The following are to be provided for continued use:
- A. Re-evaluation by the treating medical professional must be completed no earlier than 61 days after initiating therapy.
  - B. Documentation of the persistence of the disease process for which HVD has been prescribed.
  - C. Medical records must document that the member is compliant with and benefitting from HVD.
  - D. At least 30 consecutive days of device data, beginning after 31 days of initiation, demonstrating that the member is utilizing the device an average of 6 hours per 24-hour period.
- NOTE:** Failure of the member to consistently use HVD for an average of 6 hours per 24-hour period would demonstrate non-compliant utilization of the device for its intended purpose and expectation of benefit, which would

constitute a denial in continued coverage as *not reasonable and necessary*.

E. Additional information as requested.

VI. In accordance with Rule 5160-10-01 for each claim, the provider cannot legitimately receive payment until necessary supporting documents have been obtained and placed in the provider's files. These documents include the prescription and the following items:

A. A completed CMN form: ODM 01902.

B. Practitioner order and chart notes, which support the determination of medical necessity, including ventilator settings.

VII. Regardless of its authorized length, a rental period ends when the rented item is no longer medically necessary.

VIII. Exclusions

Any request for a non-invasive home ventilator (E0466) that does not meet the medical-necessity criteria outlined above will be denied as not medically necessary. This includes requests where the device is used solely as a respiratory assist device to augment spontaneous breathing or to treat sleep-disordered breathing, rather than to provide life-sustaining, non-invasive mechanical ventilation beyond the capabilities of respiratory assist devices such that withdrawal would place the member at risk of serious harm or death. Devices and modes that function as RAD—including CPAP, auto-titrating PAP, standard bilevel positive airway pressure (BIPAP), and volume-targeted pressure support modes such as AVAPS (with or without auto EPAP (AE), or iVAPS—do not qualify for coverage under E0466 when used for sleep apnea or mild to moderate respiratory insufficiency and do not, by themselves, establish ventilator dependency under this policy.

E. Conditions of Coverage

I. Claims for ventilators being utilized to provide CPAP or BIPAP therapy for conditions described above and are submitted with HCPCS code E0466, will be denied as not being reasonable and necessary. If a HVD is dispensed to a Member for CPAP or BIPAP therapy, the claim must be coded in accordance with CareSource policy, *Positive Airway Pressure Devices for Pulmonary Disorders Continued Rental*. All requirements in D. I.-V. of this policy must be satisfied for HVD to be considered medically necessary.

II. CareSource may verify the use of the equipment through post-payment audit and request additional supporting medical record documentation. If the use of a more appropriate code or piece of equipment is warranted, CareSource may request recoupment. Standard DME documentation requirements can be located within section D.II.A. of the administrative policy, *Medical Record Documentation Standards for Practitioners*.

#### F. Related Policies/Rules

DMEPOS: Positive Airway Pressure Devices, OHIO ADMIN. CODE 5160-10-19 (2025)  
DMEPOS: Respiratory Assist Devices, OHIO ADMIN. CODE 5160-10-38 (2025)  
Positive Airway Pressure Devices for Pulmonary Disorders Continued Rental  
Overpayment Recovery  
Medical Record Documentation Standards for Practitioners

#### G. Review/Revision History

|                       | DATE                     | ACTION                                                                                                                                                                                                                                                                                         |
|-----------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Date Issued</b>    | 05/22/2024               | New Policy, Approved at Committee                                                                                                                                                                                                                                                              |
| <b>Date Revised</b>   | 06/04/2025<br>05/20/2026 | Annual review: Added E.II., Updated Exclusions to include AVAPS, EPAP, iVAPS; Approved at Committee<br>AHI definition revised & definitions added under RAD; D.V.D. increased avg. device usage to 6 hours (from 4). <i>Medical Record Documentation</i> added to E.II. Approved at Committee. |
| <b>Date Effective</b> | 10/01/2026               |                                                                                                                                                                                                                                                                                                |
| <b>Date Archived</b>  |                          |                                                                                                                                                                                                                                                                                                |

#### H. References

1. Coleman JM, Wolfe LF, Kalhan R. Noninvasive ventilation in chronic obstructive pulmonary disease. *Ann Am Thorac Soc.* 2019;16(9):1091-1098. doi:10.1513/AnnalsATS.201810-657CME
2. DMEPOS: Ventilators, OHIO ADMIN. CODE 5160-10-22 (2021).
3. Janssen DJA. Assessment and management of dyspnea in palliative care. UpToDate. Updated October 29, 2025. Accessed April 1, 2026. www.uptodate.com
4. Durable Medical Equipment, Prostheses, Orthoses, and Supplies (DMEPOS): General Provisions, OHIO ADMIN. CODE 5160-10-01 (2026).
5. Ferrell BR, Twaddle ML, Melnick A, et al. National Consensus Project clinical practice guidelines for quality palliative care guidelines, 4th edition. *J Palliative Med.* 2018;21(12):1684-1689. doi:10.1089/jpm.2018.04311684
6. Freedman N. Treatment of obstructive sleep apnea: choosing the best positive airway pressure device. *Sleep Med Clin.* 2020;15(2):205-218. doi:10.1016/j.jsmc.2020.02.007
7. Gay PC. Nocturnal ventilatory support in COPD. UpToDate. Updated April 21, 2025. Accessed April 1, 2026. www.uptodate.com
8. Gay PC, Owens RL; ONMAP Technical Expert Panel. Executive summary: optimal NIV Medicare access promotion: a technical expert panel report from the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. *Chest.* 2021;160(5):1808-1821. doi:10.1016/j.chest.2021.05.074
9. Hansen-Flaschen J, Ackrivo J. Practical guide to management of long-term noninvasive ventilation for adults with chronic neuromuscular disease. *Resp Care.* 2023;68(8):1123-1157. doi:10.4187/respcare.10349
10. Hill NS, Kramer NR. Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: patient selection and alternative modes

- of ventilatory support. UpToDate. Updated November 06, 2025. Accessed April 1, 2026. [www.uptodate.com](http://www.uptodate.com)
11. Home Ventilator (Invasive or Noninvasive Interface): ACG A-0893. MCG Health. 29th ed. Accessed April 1, 2026. [www.careweb.careguidelines.com](http://www.careweb.careguidelines.com)
  12. Khan A, Frazer-Green L, Amin R, et al. Respiratory management of patients with neuromuscular weakness: an American College of Chest Physicians clinical practice guideline and expert panel report. *Chest*. 2023;164(2):394-413. doi:10.1016/j.chest.2023.03.011
  13. Kline LR. Clinical presentation and diagnosis of obstructive sleep apnea in adults. UpToDate. Updated November 25, 2025. Accessed April 1, 2026. [www.uptodate.com](http://www.uptodate.com)
  14. MacIntyre NR, Epstein SK, Carson S, et al; National Association for Medical Direction of Respiratory Care. Management of patients requiring prolonged mechanical ventilation: report of a NAMDRRC consensus conference. *Chest*. 2005;128(6):3937-3954. doi:10.1378/chest.128.6.3937
  15. Macrea M, Oczkowski S, Rochweg B, et al. Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease: an official American Thoracic Society clinical practice guideline. *Am J Resp Crit Care Med*. 2020;202(4):e74-e87. doi:10.1164/rccm.202006-2382ST
  16. Martin TJ. Noninvasive positive airway pressure therapy for obesity hypoventilation syndrome. UpToDate. Updated May 1, 2025. Accessed April 1, 2026. [www.uptodate.com](http://www.uptodate.com)
  17. Mitchell RB, Archer SM, Ishman SL, et al. Clinical practice guideline: tonsillectomy in children (update). *Otolaryngology Head Neck Surg*. 2019;160(1S):S1-S42. doi:10.1177/0194599818801757
  18. Raveling T, Vonk J, Struik FM, et al. Chronic non-invasive ventilation for chronic obstructive pulmonary disease: review. *Cochrane Database Syst Rev*. 2021;8:CD002878. doi:10.1002/14651858.CD002878.pub3
  19. Restrepo RD, Walsh BK. Humidification during invasive and noninvasive mechanical ventilation 2012: AARC clinical practice guideline. *Respir Care*. 2012;57(5):782-788. doi:10.4187/respcare.01766
  20. Sauthier M, Rose L, Juvet P. Pediatric prolonged mechanical ventilation: considerations for definitional criteria. 2017;62(1):49-53. doi:10.4187/respcare.04881
  21. van den Biggelaar RJM, Hazenberg A, Cobben NAM, et al. A randomized trial of initiation of chronic noninvasive mechanical ventilation at home vs in-hospital in patients with neuromuscular disease and thoracic cage disorder. *Chest*. 2020;158(6):2493-2501. doi:10.1016/j.chest.2020.07.007